Related Experiment Video

Updated: May 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

Edward Cha1, Eric J Small

  • 1Department of Medicine, University of California, San Francisco, California 94143, USA. edward.cha@ucsf.edu

Cancer Medicine
|May 2, 2013
PubMed

Insights

New immunotherapies, like ipilimumab, show promise in treating advanced prostate cancer. This immune checkpoint inhibitor is being studied for its potential to improve patient outcomes in castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Advanced prostate cancer treatment is becoming more complex with new therapeutic options.
  • Immunotherapeutics, which harness the patient's immune system, are a promising area of research.
  • Castration-resistant prostate cancer (CRPC) presents unique challenges requiring novel treatment strategies.

Purpose of the Study:

  • To investigate the efficacy and safety of ipilimumab, an immune checkpoint inhibitor, in advanced prostate cancer.
  • To evaluate ipilimumab's potential to augment anti-tumor immune responses by blocking cytotoxic T-lymphocyte antigen 4 (CTLA-4).
  • To explore ipilimumab's role as monotherapy or in combination with other treatments for CRPC.

Main Methods:

  • Review of seven Phase 1 and 2 clinical trials involving ipilimumab in advanced prostate cancer patients.
  • Evaluation of various doses, schedules, and combinations of ipilimumab.
  • Analysis of safety data from melanoma trials and ongoing prostate cancer studies.

Main Results:

  • Ipilimumab demonstrates activity in prostate cancer, both as a single agent and in combination therapies.
  • Observed adverse event profile is consistent with known safety data from advanced melanoma treatment.
  • Ongoing Phase 3 trials aim to further define the risk/benefit profile in different CRPC patient populations.

Conclusions:

  • Ipilimumab shows potential as an immunotherapeutic agent for advanced prostate cancer, including CRPC.
  • Combination strategies and further risk/benefit characterization are key areas of ongoing research.
  • Immune checkpoint blockade represents an exciting new frontier in prostate cancer treatment.
Keywords:
Castration-resistant prostate cancercheckpoint blockadeimmune responseimmunotherapyipilimumab

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...